New drug aims to shrink nasal polyps and improve breathing

NCT ID NCT05281523

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This Phase 3 study tested an injectable drug called depemokimab in 264 adults with chronic sinusitis and troublesome nasal polyps. The goal was to see if the drug could safely reduce polyp size and improve symptoms like nasal blockage and loss of smell over 52 weeks. Participants received either the drug or a placebo in a blinded study to compare results.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Tucson, Arizona, 85724, United States
GSK Investigational Site

Roseville, California, 95661, United States
GSK Investigational Site

New Haven, Connecticut, 06520, United States
GSK Investigational Site

Hialeah, Florida, 33012, United States
GSK Investigational Site

Baltimore, Maryland, 21287, United States
GSK Investigational Site

Grand Rapids, Michigan, 55446, United States
GSK Investigational Site

Columbia, Missouri, 65212, United States
GSK Investigational Site

Oklahoma City, Oklahoma, 73120, United States
GSK Investigational Site

Fort Worth, Texas, 76109, United States
GSK Investigational Site

McAllen, Texas, 78503, United States
GSK Investigational Site

McKinney, Texas, 75070, United States
GSK Investigational Site

San Antonio, Texas, 78258, United States
GSK Investigational Site

Norfolk, Virginia, 23507, United States
GSK Investigational Site

Morgantown, West Virginia, 26506-9200, United States
GSK Investigational Site

Changsha, 410013, China
GSK Investigational Site

Chengdu, 610041, China
GSK Investigational Site

Guangzhou, 510000, China
GSK Investigational Site

Hangzhou, 310000, China
GSK Investigational Site

Nanjing, 210009, China
GSK Investigational Site

Shanghai, 200003, China
GSK Investigational Site

Shanghai, 200031, China
GSK Investigational Site

Suzhou, China
GSK Investigational Site

Wuhan, 430060, China
GSK Investigational Site

Xiamen, 361004, China
GSK Investigational Site

Zhongshan, 528400, China
GSK Investigational Site

Zibo Shandong Province, 255036, China
GSK Investigational Site

Bologna, 40139, Italy
GSK Investigational Site

Catania, 95123, Italy
GSK Investigational Site

Milan, 20132, Italy
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Padua, 35100, Italy
GSK Investigational Site

Pisa, Italy
GSK Investigational Site

Roma, 00128, Italy
GSK Investigational Site

Roma, 00168, Italy
GSK Investigational Site

Rozzano MI, 20089, Italy
GSK Investigational Site

Varese, 21100, Italy
GSK Investigational Site

Aichi, 471-8513, Japan
GSK Investigational Site

Chiba, 262-0015, Japan
GSK Investigational Site

Chiba, 272-0143, Japan
GSK Investigational Site

Gunma, 373-8585, Japan
GSK Investigational Site

Hyōgo, 650-0047, Japan
GSK Investigational Site

Hyōgo, 665-0827, Japan
GSK Investigational Site

Ibaraki, 309-1793, Japan
GSK Investigational Site

Kanagawa, 211-8533, Japan
GSK Investigational Site

Nagano, 395-8505, Japan
GSK Investigational Site

Shiga, 525-8585, Japan
GSK Investigational Site

Shizuoka, 420-0853, Japan
GSK Investigational Site

Tokyo, 142-8666, Japan
GSK Investigational Site

?Od?, 90-153, Poland
GSK Investigational Site

Gdansk, 80-214, Poland
GSK Investigational Site

Katowice, 40-611, Poland
GSK Investigational Site

Krakow, 30-033, Poland
GSK Investigational Site

Krakow, 31-513, Poland
GSK Investigational Site

Lubin, 59-300, Poland
GSK Investigational Site

Nadarzyn, 05-830, Poland
GSK Investigational Site

Poznan, 60-355, Poland
GSK Investigational Site

Strzelce Opolskie, 47-100, Poland
GSK Investigational Site

Brasov, 500091, Romania
GSK Investigational Site

Brasov, 500283, Romania
GSK Investigational Site

Bucharest, 014146, Romania
GSK Investigational Site

Bucharest, 014452, Romania
GSK Investigational Site

Cluj-Napoca, 400349, Romania
GSK Investigational Site

Timișoara, 300643, Romania
GSK Investigational Site

Barcelona, 08022, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Barcelona, 08041, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Jerez de la Frontera, 11407, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Pamplona, 31008, Spain
GSK Investigational Site

Santander, 39008, Spain
GSK Investigational Site

Seville, 41009, Spain
GSK Investigational Site

Valladolid, 47005, Spain
GSK Investigational Site

Zaragoza, 50009, Spain
GSK Investigational Site

Gothenburg, SE-413 45, Sweden
GSK Investigational Site

Lund, SE-221 85, Sweden
GSK Investigational Site

Stockholm, SE-114 86, Sweden
GSK Investigational Site

Stockholm, SE-171 76, Sweden
GSK Investigational Site

Ankara, 06230, Turkey (Türkiye)
GSK Investigational Site

CapaIstanbul, 34093, Turkey (Türkiye)
GSK Investigational Site

Izmir, 35330, Turkey (Türkiye)
GSK Investigational Site

Tekirdağ, 59100, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.

NASAL POLYPS